OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Silverstein on Oncoplasty Versus Mastectomy for Patients With Breast Cancer

July 31st 2015

Melvin J. Silverstein, MD, FACS, medical director, Hoag Breast Center, Gross Family Foundation Endowed Chair in Oncoplastic Breast Surgery, Hoag Memorial Hospital Presbyterian, compares oncoplastic surgery with mastectomy for patients with breast cancer.

Dr. Hashemi Sadraei Discusses Biomarkers in HPV-Induced Tumors

July 30th 2015

Nooshin Hashemi Sadraei, MD, assistant professor of medicine, Department of Internal Medicine, University of Cincinnati, discusses biomarkers in HPV-induced tumors, including cervical, anal, and oropharyngeal cancers.

Dr. Edith Mitchell on Cancer Disparities Among African American Patients

July 29th 2015

Edith Mitchell, MD, Prof of Medicine and Medical Oncology at Thomas Jefferson University, Director of the Center to Eliminate Cancer Disparities at the Sidney Kimmel Cancer Center at Thomas Jefferson University, discusses racial disparities in breast and prostate cancer.

Dr. Yee on Neoadjuvant Pertuzumab in HER2-Positive Breast Cancer

July 29th 2015

Douglas Yee, MD, professor of medicine and pharmacology, Hematology, Oncology and Transplantation, Department of Medicine, medical oncologist, University of Minnesota, discusses the research that led to the FDA approval of neoadjuvant pertuzumab as part of a combination regimen for patients with HER2-positive breast cancer.

Dr. O'Sullivan on Radium-223 With Enzalutamide and Abiraterone in mCRPC

July 28th 2015

Joe O'Sullivan, MD, discusses the efficacy of radium-223 when combined with enzalutamide and/or abiraterone in an international early access program for the treatment of patients with metastatic castration-resistant prostate cancer.

Dr. Thaker on EGEN-001 Combined With Doxorubicin for Ovarian Cancer

July 28th 2015

Premal H. Thaker, MD, MS, discusses a phase I study examining the combination of EGEN-001 and doxorubicin for the treatment of patients with platinum-resistant ovarian cancer.

Dr. Jeffrey Trent on the Melanoma Dream Team

July 27th 2015

Jeffrey M. Trent, MD, president and research director, Translational Genomics Research Institute, discusses the Stand Up to Cancer-Melanoma Research Alliance Dream Team.

Dr. Arber on Aspirin for Colorectal Cancer Prevention

July 27th 2015

Nadir Arber, MD, MHA, Yechiel and Helen Lieber Chair for Cancer Research at Tel Aviv Sourasky Medical Center and Tel Aviv University, Sackler School of Medicine, Professor of Medicine and Gastroenterology and Director of the Integrated Cancer Prevention Center (ICPC) in Tel-Aviv Medical Center, discusses the role of aspirin in the prevention of colorectal cancer.

Dr. Meng on MRI-US Fusion Targeted Biopsy for High-Grade Prostate Cancer

July 24th 2015

Xiaosong Meng, MD, PhD, NYU Langone Medical Center, discusses MRI-US fusion targeted biopsies and how they can be used to identify high-grade prostate cancers.

Dr. George Demetri on Trabectedin for Sarcomas

July 24th 2015

George D. Demetri, MD, Director, Center for Sarcoma and Bone Oncology Senior Vice President for Experimental Therapeutics, Professor of Medicine, Harvard Medical School, Dana Farber Cancer Center, discusses a phase III study of trabectedin verus dacarbazine for the treatment of patients with advanced liposarcoma (LPS) or leiomyosarcoma (LMS).

Dr. Sekulic on Molecular Testing in Advanced Melanoma

July 23rd 2015

Aleksandar Sekulic, MD, PhD, chief resident associate, Dermatology, Clinician Investigator Training Program, Mayo Clinic, discusses the rationale for molecular testing in patients with advanced melanoma.

Dr. Bruce D. Cheson on Obinutuzumab/ Bendamustine Survival Benefit in iNHL

July 23rd 2015

Bruce D. Cheson, MD, Professor of Medicine, Head of Hematology, Deputy Chief, Division of Hematology/Oncology, Georgetown University Hospital, Lombardi Comprehensive Cancer Center, discusses the phase III GADOLIN study, which looks at the anti-CD20 agent obinutuzumab (Gazyva) and bendamustine compared with bendamustine alone in patients with relapsed indolent non-Hodgkin lymphoma (iNHL).

Dr. Luis A. Diaz, Jr. on Pembrolizumab For MMR-Deficient Colorectal Cancer

July 23rd 2015

Luis A. Diaz, Jr. MD, associate professor of Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, discusses the efficacy of PD-1 inhibitor pembrolizumab (Keytruda) in heavily pretreated colorectal cancer patients with mismatch repair (MMR).

Dr. Infante on Avelumab's Potential in Ovarian Cancer

July 22nd 2015

Jeffrey R. Infante, MD, director, Drug Development Program, Sarah Cannon Research Institute, discusses the potential impact avelumab could have on the treatment of patients with ovarian cancer.

Dr. Jeffrey Jones on Idelalisib Combinations in CLL

July 22nd 2015

Jeffrey Jones, MD, MPH, Assistant Professor of Internal Medicine and section head of the Chronic Lymphocytic Leukemia (CLL) research program at Ohio State University, discusses idelalisib (Zydelig) combinations in CLL.

Dr. Villaflor on RAVD of Radiotherapy With Induction Chemotherapy in HNSCC

July 21st 2015

Victoria M. Villaflor, MD, medical oncologist, associate professor of medicine, The University of Chicago Medicine, discusses findings from a response-adapted volume de-escalation of radiotherapy using induction chemotherapy in locally advanced head and neck squamous cell cancer.

Dr. Kass on Testing for HER2-Positive Breast Cancer

July 20th 2015

Fred C. Kass, MD, oncology/hematology, internal medicine, Cancer Center of Santa Barbara, gives advice for community-based oncologists regarding HER2 testing and interpretation of the results.

Dr. Nanda on Immunotherapy in Metastatic TNBC

July 18th 2015

Rita Nanda, MD, assistant professor of Medicine, associate director, Breast Medical Oncology, The University of Chicago Medicine, discusses the efficacy of pembrolizumab and atezolizumab for the treatment of patients with metastatic triple-negative breast cancer.

Dr. Chlebowski on Dietary Modifications in Patients With Breast Cancer

July 17th 2015

Rowan T. Chlebowski, MD, PhD, professor and chief, Harbor-University of California, Los Angeles Medical Center, Department of Internal Medicine, Medical Oncology/Hematology, discusses a planned follow-up analysis of the Women's Health Initiative Dietary Modification study, which examined the impact of reduced dietary fat intake in patients with breast cancer.

Dr. Tolaney on Platinum-Based Therapy in Neoadjuvant Setting of TNBC

July 16th 2015

Sara M. Tolaney, MD, MPH, physician, instructor in medicine, Harvard Medical School, medical oncologist, Dana-Farber Cancer Institute, discusses adding platinum-based therapy to the neoadjuvant setting for the treatment of patients with triple-negative breast cancer.